Denali Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.088; its P/E ratio is -16.77; Denali Therapeutics is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-0.70. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	$ 294.12M	$ 35.14M	-	$ 3.56M
Gross Profit	-	$ 294.12M	$ 35.14M	-	-
EBIT	$ -119.44M	$ 183.38M	$ 202.13M	-	$ -107.49M
EBITDA	$ -117.29M	$ 185.67M	$ 212.18M	-	$ -105.34M
Net Income Common Stockholders	$ -119.47M	$ 183.38M	$ 202.13M	-	$ -103.30M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 1.03B	$ 1.19B	$ 1.29B	$ 1.34B	$ 1.11B
Total Assets	$ 1.15B	$ 1.31B	$ 1.41B	$ 1.46B	$ 1.23B
Total Debt	$ 44.98M	$ 55.52M	$ 57.09M	$ 53.03M	$ 62.05M
Net Debt	$ -989.53M	$ -1.14B	$ -1.23B	$ -1.28B	$ -1.04B
Total Liabilities	$ 122.96M	$ 118.91M	$ 442.64M	$ 417.81M	$ 416.30M
Stockholders Equity	$ 1.03B	$ 1.19B	$ 966.71M	$ 1.04B	$ 811.30M
Cash Flow	-
Free Cash Flow	$ -100.89M	$ -119.02M	$ -61.59M	-	$ -63.10M
Operating Cash Flow	$ -98.66M	$ -113.17M	$ -58.80M	-	$ -57.05M
Investing Cash Flow	$ 73.05M	$ 168.07M	$ -92.72M	-	$ 15.42M
Financing Cash Flow	$ 4.71M	$ 9.02M	$ 1.60M	-	$ 5.15M

Currency in USD

Denali Therapeutics Earnings and Revenue History

Income Statement >

Denali Therapeutics Debt to Assets

Balance Sheet >

Denali Therapeutics Cash Flow

Cash Flow >

Denali Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing